Search

everythinglearnresearchcommunity

for

Search:↓

Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.

Experts recommend personalized treatment plans for alopecia areata, using corticosteroids and minoxidil for mild cases, and stronger medications for severe cases.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

Off-label treatments are heavily used for alopecia areata due to limited approved options.

Accurate diagnosis is crucial for effective treatment of similar hair loss conditions.

Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

The combination treatment showed a higher response rate but no significant survival benefits.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Upadacitinib improved multiple immune-related conditions in one patient.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Nilotinib can cause keratosis pilaris, a skin condition.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.